SCHEMBL429271

SCHEMBL429271

O=C(O)c1cc(Br)cnc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.48
AKR1C2 P52895 2/20 0.48
AKR1C1 Q04828 2/20 0.48
AKR1C4 P17516 1/20 0.48
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 3/20 0.44
POLB P06746 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
GLA P06280 1/20 0.42
OPRK1 P41145 1/20 0.41
HSD17B10 Q99714 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
SORT1 Q99523 4/20 0.38
ASPH Q12797 1/20 0.37
KDM8 Q8N371 1/20 0.37
CES2 O00748 1/20 0.36
GALR3 O60755 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29442199 0.82 KDM4E (0.40) AKR1C3AKR1C2AKR1C1AKR1C4KDM4E
SCHEMBL16828742 0.82 KDM4E (0.40) AKR1C3AKR1C2AKR1C1AKR1C4KDM4E
SCHEMBL1505655 0.81 KDM4E (0.45) AKR1C3AKR1C2AKR1C1AKR1C4KDM4E
SCHEMBL617721 0.79 KDM4E (0.44) AKR1C3AKR1C2AKR1C1AKR1C4KDM4E
SCHEMBL14763781 0.79 GSK3B (0.38) AKR1C3AKR1C2AKR1C1AKR1C4KDM4E
SCHEMBL4701685 0.78 CA12 (0.45) KDM4EALDH1A1POLBHSD17B10ASPH
SCHEMBL427374 0.78 SMN1; SMN2 (0.46) AKR1C3AKR1C2AKR1C1AKR1C4KDM4E
SCHEMBL1516793 0.78 NAPRT (0.46) AKR1C3AKR1C2AKR1C1AKR1C4KDM4E
SCHEMBL473906 0.78 KDM4E (0.46) AKR1C3AKR1C2AKR1C1AKR1C4KDM4E
SCHEMBL836163 0.78 KMT2A (0.52) AKR1C3AKR1C2AKR1C1AKR1C4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP claimed
US-20240011009-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2024-01-11 US claimed
US-20230220589-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2023-07-13 US claimed
EP-4127157-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2023-02-08 EP claimed
WO-2022072560-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2022-04-07 WO claimed
CN-111995568-B Preparation method of poly-substituted fluorine-containing hexa-heterocyclic methylamine with protection groups 北京六合宁远科技有限公司 2022-04-05 CN claimed
WO-2021194908-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2021-09-30 WO claimed
CN-111995568-A Preparation method of poly-substituted fluorine-containing hexa-heterocyclic methylamine with protection groups 北京六合宁远科技有限公司 2020-11-27 CN claimed
US-4960896-A Halogenation with hypohalite salts A. H. ROBINS COMPANY, INC. (US) 1990-10-02 US claimed
EP-0225172-A1 Process for the preparation of 5-chloro and 5-bromo-2-hydroxynicotinicacids A.H. ROBINS COMPANY, INCORPORATED (US) 1987-06-10 EP claimed
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP disclosed
US-12466822-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2025-11-11 US disclosed
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE INCYTE CORP (US) 2025-10-23 US disclosed
EP-4573085-A1 SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS Glenmark Pharmaceuticals Limited (IN) 2025-06-25 EP disclosed
EP-4568951-A1 HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2025-06-18 EP disclosed
US-4705853-A ANTIHISTAMINES A. H. ROBINS COMPANY, INC. (US) 1987-11-10 US disclosed
EP-0225172-A1 Process for the preparation of 5-chloro and 5-bromo-2-hydroxynicotinicacids A.H. ROBINS COMPANY, INCORPORATED (US) 1987-06-10 EP disclosed
US-4642343-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1987-02-10 US disclosed
US-4604388-A Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof in a method of counteracting histamine A. H. ROBINS COMPANY, INCORPORATED (US) 1986-08-05 US disclosed
US-4592866-A Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof A. H. ROBINS COMPANY, INC. (US) 1986-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE CD274, PDCD1LG2, PDCD1 AKR1C3 4513/4885AKR1C2 4529/4885AKR1C1 4564/4885
US-12466822-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS AKR1C3 693/4885AKR1C2 1077/4885AKR1C1 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.